Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Séquence:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Numéro de cas. : 159519-65-0
Formule moléculaire : C204H301N51O64
Poids moléculaire : 4492
Pureté (HPLC) : 98.0%min.
Apparence : White to off-white amorphous solid
Impureté unique (HPLC) : 0.5%maximum
Composition en acides aminés : ±10% of theoretical
Contenu peptidique (N%) : ≥80,0%
Teneur en eau (Karl Fischer) : ≤8,0%
TrifluoroAcetate Content(HPIC) : ≤12,0%
MS (ESI) : Consistent
Bilan de masse : 95.0~105,0%
Grade : Qualité pharmaceutique
Stockage: Closed, below 2 ~ 8℃ preservation
Usage : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (AUBERGE) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
